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Abstract  
Background. The treatment of systemic sclerosis (SSc) represents a great clinical 
challenge because of the complex disease pathogenesis including vascular, fibrotic, 
and immune T- and B-lymphocyte-mediated alterations. Therefore, SSc should be 
treated by combined or sequential therapies according to prevalent clinico-
pathogenetic phenotypes. Some preliminary data suggest that rituximab (RTX) may 
downregulate the B-cell over expression and correlated immunological 
abnormalities.  
Methods. Here, we describe a series of 10 SSc patients (4 M and 6 F, mean age 
46±13.5SD years, mean disease duration 6.3±2.7SD years; 5 pts had limited and 5 
diffuse SSc cutaneous subset) treated with one or more cycles of RTX (4 weekly 
infusions of 375 mg/m2). The main indications to RTX were interstitial lung fibrosis, 
cutaneous, and/or articular manifestations unresponsive to previous therapies; 
ongoing treatments remained unchanged in all cases. The effects of RTX were 
evaluated after 6 months of the first cycle and at the end of long-term follow-up 
period (37±21SD months, range 18-72 months).   
An updated review of the world literature was also done. 
Results. RTX significantly improved the extent of skin sclerosis in patients with 
diffuse SSc at 6 months evaluation (modified Rodnan skin score from 25±4.3 to 
17.2±4.6; p =.022). A clinical improvement of other cutaneous manifestations, 
namely hypermelanosis (7/7), pruritus (6/8), and calcinosis (3/6) was observed. 
Moreover, arthritis revealed particularly responsive to RTX showing a clear-cut 
reduction of swollen and tender joints in 7/8 patients; while lung fibrosis detected in 
8/10 remained stable in 6/8 and worsened in 2/8 at the end of follow-up. Pro-
inflammatory cytokines, namely IL6, IL15, IL17, and IL23, evaluated in 3 patients 
with diffuse cutaneous SSc, showed a more or less pronounced reduction after the 
first RTX cycle. 
These observations are in keeping with the majority of previous studies including 6 
single case reports and 10 SSc series (from 5 to 43 pts), which frequently reported 
the beneficial effects of RTX on some SSc manifestations, particularly cutaneous 
sclerosis, along with the improvement/stabilization of lung fibrosis. Possible 
discrepancies among different clinical studies can be related to the etiopathogenetic 
complexity of SSc and not secondarily to the patients’ selection and disease 
duration at the time of the study.  
Conclusion. The present study and previous clinical trials suggest a possible 
therapeutical role of RTX in SSc, along with its good safety profile. The specific 
activity of RTX on B-cell-driven autoimmunity might explain its beneficial effects on 
some particular SSc clinical symptoms, namely the improvement of skin and 
articular involvement, and possibly the attenuation of lung fibrosis. 
 
 
 
 
 
1.Introduction                                                                                                    
Systemic sclerosis (SSc) is a connective tissue disease characterized by specific 
autoimmune abnormalities, diffuse microangiopathy, and accumulation of collagen 
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and other matrix constituents in the skin and target internal organs [1, 2]. Clinically, 
SSc appears as multifaceted disorder consequent to the variable contribution of the 
above pathogenetic mechanisms, through a multistep process responsible for 
different clinical phenotypes. These latter represent a variable combination and 
degree of typical SSc symptoms: from vascular manifestations, i.e. skin ulcers, 
pulmonary arterial hypertension, and/or renal scleroderma crisis, to fibrotic 
cutaneous and visceral organ involvement [1-4]. Abnormal humoral and cellular 
immune activation may decisively contribute to both vascular and fibrotic SSc 
manifestations [1-4]; however, the complex and pleiotropic nature of the immune 
response in SSc constitutes a great therapeutic challenge [1-6]. The effects of 
nonselective immunosuppressive treatments, usually employed during the early 
phases of SSc to control skin and lung inflammation, are often unpredictable. In 
addition, they tend to lose their efficacy once the disease enters a chronic phase, 
and consequently their long-term treatment is not recommendable considering their 
potential severe side-effects [4].  
Given the close interrelationship between altered immune response and 
initiation/propagation of the other SSc pathogenetic events, the usefulness of novel 
immunomodulating therapies targeting specific cellular and/or molecular immune 
effectors requires to be carefully investigated [6]. In particular, the rationale for the 
use of rituximab (RTX), able to downregulate the B-cell over experession, is largely 
demonstrated in different autoimmune diseases [7-14]; moreover, some important 
experimental data suggested a key role for B cells in regulating both inflammatory 
and fibrotic alterations that characterize several SSc manifestations [4, 6, 15, 16]. 
On the basis of laboratory investigations, during the last years preliminary clinical 
trials have suggested the therapeutical usefulness of RTX also in SSc [17-18].  
Here we report our experience with RTX treatment in a series of SSc patients along 
with the updated review of the world literature on this topic. 
 
 
1.1. Patients and methods 
The present study included 10 SSc patients (4 M and 6 F, mean age 46 ± 13.5SD 
years, mean disease duration 6.3 ± 2.7 SD years) treated with one or more cycles 
of RTX and evaluated during a mean follow-up period of 37±21SD months, range 
18-72 months (Tab. 1). All patients, followed at our University-based Rheumatology 
Unit, satisfied EULAR/ACR 2013 criteria for SSc classification [19].  
Scleroderma cutaneous and visceral organ involvement, including pulmonary, 
cardiac, renal, and gastrointestinal alterations, as well as routine blood chemistry, 
urinalysis, and immunological alterations were evaluated according to previously 
described methodologies  [3, 5]. The following serological markers were detected by 
means of standard techniques: anti-nuclear (ANA), anti-centromere (ACA), anti-
nucleolar (ANoA), and anti-extractable nuclear antigen (ENA) antibodies; these 
latter included anti-Scl70, -Sm, -RNP, -SSB, -SSA, -PCNA, -SL, and Jo1 [3]. 
In addition, standard pulmonary function tests (PFTs), namely FVCnd a DLCO, 6-
minute walking test, high-resolution computed tomography (HRCT), trans-thoracic 
echo-color-Doppler cardiography (ECHOcg), and nailfold videocapillaroscopy were 
performed in all patients at baseline, after 6 months of RTX treatment, and at the 
end of follow up. With the same timing, an experienced physician evaluated, in a 
blinded fashion, the extent of skin thickening measured by modified Rodnan skin 
score (mRSS), the presence and severity of skin ulcers, melanodermia, 
teleangectasias, calcinosis, pruritus, and tender and/or swelling joints. Four patients 
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with abnormally increased pulmonary arterial systolic pressure at ECHOcg 
underwent to right heart catheterization. 
All patients gave their written informed consent to enter in the study. 
At the starting of RTX treatment, the patients showed one or more active SSc 
clinical manifestations, scarcely responsive to previous and/or ongoing treatments 
(Tab. 1). Patients were treated with one or more cycles of RTX; each cycle included 
4 infusions of RTX 375 mg/m2 of body surface area once weekly, always in 
combination with other ongoing therapies (iloprost, calcium-channel blockers, 
steroids and/or bosentan). Nine patients underwent to a second RTX cycle after 6 
months; moreover, in 4/9 subjects RTX was repeated once yearly for a total of 3-5 
cycles. In only one patient the initial RTX cycle was interrupted after the first two 
infusions because of severe sepsis. Besides routine laboratory examinations, at 
baseline and after six months of RTX therapy, circulating CD19-positive cell count 
were carried out in all cases by flow cytometry; moreover, serum levels of some 
pro-inflammatory interleukins were measured in 3 patients by means of 
commercially available assays (Human IL6, IL15, IL17, and IL23 Quantikine ELISA 
Kits). 
Adverse events attributable to RTX were also recorded; they were classified as 
adverse events that occurred during RTX infusion or that appeared within the next 
12 months after the RTC cycle and requiring hospitalization and/or intravenous 
antibiotics in case of infection. 
 
1.1.2. Review of the literature.  A throughout search in PubMed, Embase, Scopus, 
Web of Science, Asian Science Citration Index (ASCI), IranMedex, Scientific 
Information Database (SID), PaKMediNet, IndMed, and Index Medicus for the World 
Health Organization Eastern Mediterranean Region (IMEMR) regarding SSc 
patients treated with RTX up to June 2015 was done, using the key words 
scleroderma, systemic sclerosis, rituximab, and anti-CD20. 
 
1.1.3. Statistical analysis. Statistical analysis was performed by means of 
univariate analysis of variance (ANOVA), Student’s t-test, and Fisher's exact test. 
Values are given as mean±SD for normally distributed variables, or as median 
(range) for not normally distributed variables; P values ≤0.05 were considered 
statistically significant.   
 
 
1.2. Results                                                                                                     
Demographic and clinico-epidemiological features of 10 SSc patients treated along 
with the main indications to RTX therapy are shown in Tab. 1.Five patients 
presented limited cutaneous scleroderma with serum ACA, while the other five 
showed a diffuse cutaneous  involvement with circulating anti Scl-70 in 4 and ANoA 
in one. The most frequent symptoms were arthritis (8 pts), lung fibrosis (9 pts) 
associated to PAH in 4; pruritus (7 pts), melanodermia (7 pts), skin ulcers (8 pts), 
calcinosis (6 pts), and dysphagia (5 pts). RTX treatment was decided because of 
the failure or low responsiveness to other previous combined treatments (Ca-
channel blockers, iloprost, bosentan, hydroxychloroquine, leflunomide, and/or 
immunosuppressors). At baseline the patients showed a variable combination of 
SSc clinical manifestations; the main indications to RTX are shown in Tab. 1. 
After 6 months from the first RTX cycle, the patients showed a clear-cut clinical 
improvement of both articular and skin SSc manifestations. In particular, the number 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
of swollen and tender joints markedly reduced in 7/8 patients, as well as the 
patient’s pain VAS that medially decreased 66±19.5 to 39±9.9 (p=0.017). At the end 
of follow-up, the clinical improvement of arthritis showed a complete remission in 
6/7 and remained stable in 1/7.  
Similarly, mRSS was significant lower after RTX (from 15.3±11.5 to 11±7.3; 
p=0.042); skin sclerosis improvement was particularly evident considering the five 
patients with diffuse cutaneous involvement (mRSS from 25±4.3 to 17.2±4.6; p 
=.022). At the end of follow-up, the extent of skin sclerosis in the five patients with 
diffuse cutaneous subset remained stable or showed a moderate progression in 
some individuals (19.6±7.1; Wilcoxon test: p=0.071; Fig. 1).  
After RTX treatment the majority of subjects showed (Tab. 1) a clinical improvement 
of other cutaneous manifestations, such as hypermelanosis (7/7), pruritus (6/8), and 
calcinosis (3/6), with the exception of digital ulcers resulting scarcely responsive in 
all cases (6/6) (Tab. 1). 
Similarly, other important SSc manifestations were poorly responsive to RTX 
treatment; in particular lung fibrosis detected in 8/10 remained stable in 6/8 and 
worsened in 2/8 at the end of follow-up (Tab. 1); moreover, three individuals (pts no. 
1, 2, and 4) deceased because of PAH progression (Tab. 1).  
As expected, the number of circulating B-lymphocytes significantly decreased in all 
patients after RTX treatment, while no variations of serum levels of 
immunoglobulins, autoantibodies, ESR, and C-reactive protein were observed. 
Moreover, serum levels of pro-inflammatory cytokines, namely IL6, IL15, IL17, and 
IL23, measured at baseline in 3 patients with diffuse cutaneous SSc, were 
abnormally increased in all cases compared to the median values detectable in our 
healthy controls; these cytokines showed a more or less pronounced reduction after 
6-month period from the first RTX cycle (Tab. 2).  
With regards to the safety of RTX, only few and generally mild side-effects were 
recorded after treatment. In particular, infusion-related reactions were observed in 
2/10 patients, i.e. hypotension, mild urticaria, and serum sickness-like reaction. Only 
one patient developed bacterial infection of the urinary tract that needed the 
hospitalization and intravenous antibiotics, with RTX cycle discontinuation.  
 
1.2.1.Review of the literature. Available data from the world literature regarding 
the RTX treatment in SSc patients comprises 15 reports [17, 18, 20-32], which are 
carefully summarized in the Tab. 3. It includes 6 single case reports [17, 22, 24-26, 
29] and 9 open-label, uncontrolled trials [18, 20, 21, 23, 27, 28, 30- 32]; these latter 
generally reported small patients’ series (from 5 to 20 pts), with the exception of one 
multicentre study reporting the effects of RTX in a large series scleroderma patients 
[31]. The indications to RTX treatment were generally lung fibrosis and/or skin 
sclerosis, and less frequently severe calcinosis or arthritis (Tab. 3); while, the 
dosage and modalities of drug administration and the number of RTX cycles, as 
well as the duration of patient’s clinical follow-up after RTX treatment largely varied 
among different studies (Tab. 3).  
Following the first description of a patient with lung fibrosis improvement by 
McGonagle et al. in 2008 [17], the majority of studies focused on the significant 
reduction of skin sclerosis and/or improvement/stabilization of interstitial lung 
fibrosis after RTX treatment (Tab. 3).  
The improvement of lung fibrosis was observed in one randomized controlled trial 
including a small series of SSc patients [23]; in addition, RTX was able to reduce 
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the scores of skin sclerosis, even if cutaneous improvement was comparable to that 
observed in the control group of patients receiving standard treatment alone [23]. 
More recently, two studies reported the effects of RTX treatment in SSc patients 
showing a positive response of both cutaneous and pulmonary involvement [31, 32]. 
In particular, Bosello et al. demonstrated a clear-cut reduction of skin fibrosis and 
disease activity/severity indexes after RTX in the majority of patients unresponsive 
to recent treatment with cyclophosphamide [32]. Moreover, pulmonary function tests 
remained stable throughout the long-term clinical follow-up. The Authors 
hypothesized that these findings, especially the skin fibrosis improvement might be 
correlated to the significant decline in IL-6 serum levels after RTX treatment as 
observed in a previous study of the same group [20]. In a multicentre study by the 
European Scleroderma Trial and Research (EUSTAR) the efficacy and safety of 
RTX were analyzed in 63 patients using a nested case-control design [31]. The 
mRSS was available in 46 patients showed a significant reduction in the RTX-
treated group compared to matched controls (N=25; -24.0±5.2% vs -7.7±4.3%; 
p=0.03). Moreover, in RTX-treated patients, the mean mRSS was significantly 
reduced at the follow-up compared with baseline (26.6±1.4 vs 20.3±1.8; p=0.0001). 
In addition, in a limited number of patients with documented interstitial lung disease, 
RTX was able to prevent a further decline of FVC compared with controls (N=9; 
0.4±4.4% vs -7.7±3.6%; p=0.02). The safety measures showed a good profile of 
RTX in SSc patients consistent with previous studies in other autoimmune 
rheumatic diseases [31, 7-13].  
Contrarily, Lafyatis et al. did not confirm the above positive results in a study 
evaluating the effects of a single RTX cycle in a series of 15 patients with diffuse 
cutaneous SSc; no significant variations of both cutaneous and lung involvement 
were observed, regardless the complete depletion after 6-months from RTX cycle of 
the modest B cell infiltrates present in most skin biopsies at baseline [18].  
On the whole, these cohort studies demonstrated the frequent reduction of skin 
fibrosis as well as the improvement/stabilization of lung fibrosis after RTX, while 
data regarding the beneficial effects on other SSc manifestations such as 
calcinosis, arthritis, and skin ulcers remains still anecdotal.  
 
 
 
1.3. Discussion  
The results of the present study seem to confirm the clinical usefulness of RTX 
treatment in SSc patients, particularly for some disease manifestations. The B cell 
depletion was able to significantly improve the extension and severity of skin 
sclerosis, clearly evident in patients with diffuse cutaneous involvement; similarly, 
other skin manifestations, such as melanodermia, pruritus, and calcinosis 
ameliorated in the majority of individuals. Another valuable effect of RTX was the 
recovery of arthritis in 7/8 patients. Of interest, these positive effects were 
maintained for the entire long-term follow-up period. With regards to main visceral 
organ manifestations, lung and heart involvement revealed scarcely responsive at 
the first patient’s evaluation but showed a valuable stabilization (lung) at the end of 
the follow-up; on the contrary, 3/4 patients with PAH and limited cutaneous SSc 
died because of the progression of lung vascular involvement regardless combined 
vasoactive drugs and RTX treatment.  
In our experience, the most favorable results were mainly observed for skin and 
articular involvement; the improvement of skin sclerosis was clearly quantifiable in 
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patients with diffuse cutaneous SSc subset, while arthritis ameliorated in the 
majority of cases regardless of cutaneous and serological disease subsets. In three 
subjects the improvement of some clinical SSc manifestations were mirrored by the 
reduction of serum levels of some cytokines potentially involved in the pathogenesis 
of the disease [20, 32, 33, 34, 35, 36]. 
 
The above findings are in some measure comparable with that emerging from the 
updated review of the world literature on the RTX treatment in SSc patients [17, 18, 
20-32]. A limited number of open-label, uncontrolled trials are generally referred to 
small patients’ series; while only one multicentre study evaluated the effects of RTX 
in a larger number of scleroderma patients [31]. Up to date, the observed variations 
of scleroderma clinical features represent only preliminary, encouraging 
suggestions of a possible role of RTX in the therapeutical strategies of SSc. The 
indications to RTX treatment were more frequently cutaneous, pulmonary 
involvement, and/or the failure of previous treatments  [17, 18, 20-32]; while, the 
dosage and modalities of RTX administration, the number of cycles, as well as the 
duration of patient’s clinical follow-up after treatment were considerably 
heterogeneous among different trials [17, 18, 20-32]. However, these studies 
generally suggested the efficacy of RTX in the treatment of skin sclerosis along with 
the possible improvement and/or stabilization of interstitial lung fibrosis, along with 
the good safety profile of this drug [17, 18, 20-32].  
In particular, the EUSTAR multicentre study analyzed the efficacy and safety of 
RTX in a relatively large series of patients, showing that the drug was able to 
significantly improve the extent of skin sclerosis in patients with diffuse SSc subset; 
moreover, in individuals with interstitial lung disease RTX was able to prevent a 
further decline of FVC compared to controls [31]. The clinical usefulness was 
associated with elevated patients’ compliance and safety of RTX treatment as 
previously observed in other autoimmune rheumatic disorders [7-13, 17, 18, 20-32]. 
Comparable results have been demonstrated in another recent trial [32] reporting a 
significant improvement of both skin sclerosis and other SSc activity/severity 
indexes after RTX cycles in patients unresponsive to recent treatment with 
cyclophosphamide. Moreover, lung involvement remained stable throughout the 
long-term clinical follow-up. The observed cutaneous and pulmonary improvement 
was mirrored by the significant reduction of circulating IL-6 levels after RTX 
treatment, suggesting a key role of this cytokine in the pathogenesis of the disease, 
especially with regards the severity of cutaneous involvement [20].  
 
The therapeutical effects of RTX on some important SSc manifestations evidenced 
by different trials, including the present study, contrast with the results of a 
previously published report by Lafyatis et al. [18] evaluating a series of 15 patients 
with diffuse cutaneous SSc; these Authors did not find significant variations of both 
skin and lung involvement after a single RTX cycle [18].  
Some discrepancies among different clinical studies are not surprising considering 
the etiopathogenetic complexity of SSc and other variables such as the patients’ 
selection, disease duration at the time of the study, and associated treatments [17, 
18, 20-32].  Moreover, the therapeutical specificity of RTX, able to down-regulate 
the B-cell function, might explain its positive effects on some particular SSc clinical 
symptoms, i.e. the reduction of skin sclerosis and the attenuation of lung fibrosis 
[17, 20-25, 27, 28, 30-32]. SSc is the result of a multifactorial and multistep process 
secondary to different causative and genetic predisposing factors; various 
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pathogenetic processes, including endothelial cell impairment with diffuse 
microangiopathy, increased collagen deposition by altered fibroblasts, and T- and 
B-cell hyperactivity, may variably contribute to the wide spectrum of SSc clinical 
phenotypes [1-6]. In this context, anti-CD20 treatment could be included among 
different pathogenetic treatments of SSc according to specific therapeutic protocols. 
The main vascular manifestations of SSc, i.e. pulmonary arterial hypertension, renal 
crisis, and digital ulcers, must be primarily treated with vasoactive treatment [4-6]; 
while skin and internal organ involvement secondary to fibrotic and immune-
mediated alterations may be responsive to anti-fibrotic/immunosuppressive drugs 
[4-6]. These different therapeutic approaches are not mutually exclusive due to the 
frequent coexistence of different pathogenetic processes in the same individual; 
they could be employed as combined/sequential treatments according to the 
prevalent pathogenetic alterations and symptom aggregations [4-6]. Because of the 
lack of well-defined predictive factors for the appearance of specific clinical 
manifestations, the effects of different therapies are unpredictable in the clinical 
practice, as well as often inadequate or transient [4-6]. Therefore, the therapeutical 
interventions should be started in the early phases of disease or directed to single 
organ involvement and always tailored in individual patient after a careful evaluation 
of the clinico-immunological SSc phenotype; in all cases, a tight monitoring of 
patients is necessary and when necessary a timely treatment remodulation.  
If confirmed by further investigations in larger patients’ series, anti-CD20 therapy 
could be included in the therapeutic armamentarium of scleroderma patients; it 
could be positioned among the first-line treatments of patients with diffuse skin 
sclerosis and mild-moderate visceral organ involvement [17, 20-25, 27, 28, 30-32], 
as well as in the presence of SSc-associated arthritis [32 and present series]. Even 
if in a limited number of patients the clear-cut improvement of SSc-related arthritis 
represents one of the most valuable effects of RTX treatment in our experience.  
Both cutaneous and joint involvement may be responsible for the severe disability 
that lastly affects a high percentage of scleroderma patients [37, 38].                           
In the presence of most severe manifestations, such as progressive interstitial lung 
fibrosis, RTX might be usefully employed as second-line treatment after an attempt 
with antifibrotic/immunosuppressive therapy.  
  
 
 
 
 
Take-home messages. 
- B-cell overexpression represents one of the most important pathogenetic 
mechanisms of SSc 
- The usefulness of Rituximab on some SSc manifestations has been 
previously reported 
- In our SSc pts, anti-CD20 therapy was able to improve both cutaneous and 
articular involvement. 
- These findings are in keeping with the updated review of the world literature 
on this topic 
- Rituximab represents a promising treatment of SSc skin sclerosis and 
arthritis, and possibly lung involvement  
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Legend to the Fig. 1. 
Variations of modified Rodnan skin score (mRSS) after 6 months of the first 
rituximab cycle and at the end of long-term follow up (f.u.; mean 37±21SD months) 
in 10 scleroderma patients, 5 with limited (lcSSc) and 5 with diffuse cutaneous 
(dcSSc) subset. P values are referred to 5 patients with dcSSc. 
 
 
 
Tab. 1. Epidemiological and clinico-serological features of SSc patients before/after 
rituximab treatment. 
Patients 1 2 3 4 5 6 7 8 9 10 
Age/Sex 70/M 74/F 68/F 80/F 74/F 24/F 29/M 45/M 41/F 39/M 
SSc dur. (yrs) 22 13 25 20 9 3 12 2 4 5 
SSc cutaneous 
subset 
Limit
ed Limited 
Limite
d 
Limite
d Limited Diffuse Diffuse Diffuse Diffuse Diffuse 
Autoantibodies ACA ACA ACA ACA ACA ANoA anti-Scl70 
anti-
Scl70 anti-Scl70 
anti-
Scl70 
Indication to 
RTX 
L,  A  L,    A, DU  L,  C 
L,  A, 
C, DU 
L, A,   
DU, C 
A, DU,     
C, S 
L, DU,   C, 
S  L, A,   S 
L, A,   S, 
DU A, S 
RTX cycles 5 2 2 2 3 1 5 2 4 2 
Other therapies 
B, 
Ccb, 
Cs 
B, Ilo, 
Ccb, Cs 
Ilo, 
Ccb, 
Cs 
Ilo, 
Ccb, 
Cs 
Ilo, Lef, 
Ccb, Cs 
B, Ilo, 
Mmf, Ccb, 
Cs 
B, Ilo, 
Mmf, Ccb, 
Cs 
Ilo, Lef, 
Ccb, Cs 
B, Ilo, 
Mmf, Ccb, 
Cs 
B, Ilo, 
Ccb, Cs 
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Follow-up 
(months) 72 72 30 18 30 18 48 18 36 24 
Clinical features 
(baseline/6mth/end of follow-up) 
Skin  
   mRSS  6/6/6  4/4/4  6/6/6  4/4/4  4/4/4  33/22/30  24/18/20  22/20/20  24/16/18 
 
26/10/1
0 
   Digital 
ulcers° 
 -/-/-   +/+/+   -/-/-   +/+/+   +/+/+   +/+/+   +/+/+  -/-/-   +/+/+  -/-/- 
   Calcinosis 
(I/U/W)  -/-/-  -/-/-   +/u/u   +/u/u   +/u/u  +/i/i  +/i/i  -/-/-  +/i/i  -/-/- 
   
Melanodermia  +/i/u  -/-/-  -/-/-  -/-/-  +/i/u  +/i/i  +/i/i  +/i/i  +/i/i  +/i/u 
   Pruritus   -/-/-  -/-/-  +/i/u   +/u/u   +/u/u  +/i/i  +/i/i  +/i/i  +/i/i  +/i/i 
Lung^   
  
+/u/u   +/u/u   +/u/u   +/u/u   +/u/u   -/u/u  +/u/w  -/-/-  +/u/w   +/u/u 
Cardiovascula
r inv. 
   LV 
involvement 
(ECHO) 
  
+/u/u   +/u/u   -/-/-  +/u/w   -/-/-   -/-/-   -/-/-   -/-/-   -/-/-   -/-/- 
   PAH 
 
+/u/w  +/u/w   +/u/u  +/u/w   -/-/-   -/-/-   -/-/-   -/-/-   -/-/-   -/-/- 
Esophagous  
Dysphagia 
  
+/u/u  -/u/u   +/u/u  -/u/u   -/-/-   +/u/u   +/u/u   -/-/-  +/u/u   -/-/- 
Kidney  -/-/-  -/-/-  -/-/-  -/-/-  -/-/-  -/-/-  -/-/-  -/-/-  -/-/-  -/-/- 
Arthritis  +/i/u  +/i/i   -/-/-   +/u/u  +/i/i  +/i/i   -/-/-  +/i/i  +/i/i  +/i/i 
Cumulative 
results  
     6 months i (A) i (A) u u i  (A)  i (A, C, S) i (C, S) i (A, S) i (A, C, S) i (A, S) 
     end of 
follow-up u* i (A)*  u u* i (A)  i (A, C, S) i (C, S) i (A, S) i (A, C, S) i (A, S) 
                      
°digital ulcers detectd at baseline in 6/6 pts were unresponsive to RTX needing in all cases of other systemic and local 
treatments;  
^Interstitial lung involvement evaluated by means of HRCT, FVC, Dlco, and 6-minute 
walking test 
L: lung;   A: arthritis; DU: digital ulcers; C: calcinosis; S: skin involvement evaluated by modified Rodnan skin score 
(mRSS);   
i/u/w: improved/unchanged/worsened; ECHO: 
ecocolorDoppler cardiography; 
B: bosentan; Lef: leflunomide; Ilo:  iloprost; Mmf: mycophenolate mofetil; Cs: corticosteroids;   Ccb: calcium channel 
blokers 
ACA: anticentromere;   ANoA: antinucleolar; anti-Scll70: 
antitopoisomerase 1 antibodies 
*deceased due to the progression of pulmonary arterial 
hypertension (PAH); 
 
 
Tab. 2.  
Serum levels of cytokines in 3 pts with diffuse cutaneous SSc before/after rituximab 
Patient 
IL-6                   
range 0-12 pg/ml      
median 3.6*  
IL-15                 
range 0-8.68 pg/ml     
median 2.4*        
IL-17                 
range 0 – 252 pg/ml  
median 21*    
IL-23                      
range 0 – 645 pg/ml   
median 0*  
no. b / a b / a b / a b / a 
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6 98.2 / 62.5 17.4 / 12.4 30.4 / 14.8 7.9 / 1.4 
8 35.4 / 20.7 11.8 / 10.1 26.8 / 22.7 6.3 / 6.1 
9 101 / 44.5 89.9 / 36.5 70.5 / 41.9 10.1 / 4.8 
          
SSc: systemic sclerosis; RTX: rituximab 
*range and median values are referred to our healthy controls 
b / a: before/after 6-month follow-up period from the first RTX (rituximab) cycle 
 
 
 
Tab. 3. Systemic sclerosis (SSc) patients treated with 
Rituximab (RTX): review of the literature     
 
                          
Treatment with RTX    
  
 
SSc Dosage 
Cyc
les 
Follo
w-up Main 
 
Skin 
biopsy 
Adverse 
events 
N
o. 
Authors, 
year (ref. 
no.) 
Pts 
no. each cycle  no. 
mont
hs° 
indicat
ions* Results 
 
before/aft
er RTX 
serious-
minor  
1 
Mc Gonagle D, 
2008  1 
RTX 1g/2wks 
for 2 times 2 nd L 
Improved 
lung inv. 
(FVC, 
DLCO, and 
fibrosis at 
HRCT) nd na 
2 
Lafyatis R, 
2009 15 
RTX 1g/2wks 
for 2 times 1 6-12 S, L 
skin fibrosis 
and lung inv. 
remained 
stable.  
reduction 
myofibrobla
st scores,  
depletion of 
dermal B 
cells 6 
months after 
RTX cycle 
prostate 
cancer (1 pt) 
possibly  
unrelated to 
RTX;                 
infusion 
reactions 
46.7% (pts 
not 
premedicated
), mild 
hypotension 
(2 pts), 
flushing, 
fatigue, 
nausea/abdo
minal 
cramping, 
rigors, and 
hand tingling 
each (1 pts), 
urinary tract 
infection (1 
pt), dental 
abscess (1 
pt). 
3 Bosello S, 2010 9 
RTX 1g/2wks 
for 2 times 1 6-36 S, L 
Improvement 
of mRSS 
and clinical 
depletion of  
B-cell 
infiltrates (1 na 
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symptoms pt) 
4 Smith V, 2010 8 
RTX 1g/2wks 
for 2 times 1 24 S 
significant 
improvement 
of mRSS 
improvemen
t of 
myofibrobla
sts and 
collagen; 
absence of 
B cells at 
baseline 
Possibly  
unrelated to 
RTX: 1 pt 
underwent 
coronary 
artery bypass 
surger; 1 pt 
reported a 2-
day lowgrade 
fever 
occurring 2 
weeks after 
the second 
infusion. 
5 
Daoussis D, 
2010  1 
RTX 
375mg/m2/wk 
for 4 weeks  4 24 S, L 
Improved 
lung and skin 
inv. 
reduction of 
collagen 
and 
myofibrobla
st scores, 
and B-cell 
infiltrates 
Severe 
respiratory 
tract infection 
with 
hospitalization 
2 months 
after the third 
RTX course. 
6 
Daoussis D, 
2010 14 
8 pts were 
randomized 
to receive two 
cycles of RTX 
(375mg/m2/w
k for 4 weeks) 
compared to 
6 pts as 
controls 2 12 S, L 
Improved 
lung inv. 
Improvemen
t of fibrosis 
in the 
papillary 
dermis, 
reduction of 
collagen 
deposition 
and B-cell 
infiltrates  
! pt was 
hospitalized 
for respiratory 
tract infection 
3 months 
after the 
second cycle 
of RTX 
7 Haroon M, 2011 1 
RTX 1g/2wks 
for 2 times 1 12 L 
Improved 
lung inv., 
disappearan
ce of 
exertional 
dyspnoea nd na 
8 Yoo WH, 2012 1 
RTX 
500mg/wk for 
2 weeks                 1 2L 
Improved 
lung inv. 
(FVC, 
DLCO, and 
fibrosis at 
HRCT) nd na 
9 
Daoussis D, 
2012 1 
RTX 
375mg/m2/wk 
for 4 weeks  2 24 C 
Significant 
improvement 
of calcinosis  nd na 
10 
Daoussis D, 
2012^ 8 
RTX 
375mg/m2/wk 
for 4 weeks  4 24 S, L 
Improvement 
of skin and 
lung inv. 
Decrease in 
collagen 
accumulatio
n, 
myofibrobla
st score and 
skin 
infiltrating B 
cells  
Respiratory 
tract infection 
3 mths after 
second RTX 
course (1 pt). 
Respiratory 
tract infection 
with 
associated 
leukopenia 2 
mths after 
third RTX 
course, and 
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an H1N1 
infection 5 
mths after 
fourth RTX 
course (1 pt). 
Mild infusion 
reaction 
during the first 
RTX course 
(1 pt). 
11 Smith V,  2013 8 
RTX 1g/2wks 
for 2 times 2 24 S, L 
Improvement 
of skin inv. 
and 
stabilization 
of internal 
organ status  
reduction of 
collagen 
and 
myofibrobla
st scores, 
and B-cell 
infiltrates  
Coronary 
arterial 
bypass 
grafting (1 pt), 
episode of 
noninfectious 
subfebrility 
(1pt), sepsis 
leading to 
death (1 pt), 
secondary 
infection of 
digital ulcer (1 
pt), episode of 
hyperventilati
on (1) 
12 
de Paula DR, 
2013 1 
RTX 
375mg/m2/wk 
for 4 weeks  2 7 L, C 
Complete 
resolution of 
calcinosis, 
improved 
dyspnea and 
synovitis  nd na 
13 
Moazedi-Fuerst 
FC,  2014 5 
RTX 
500mg/wk for 
2 weeks 
every 3 
months for 1 
year 4** 12 S, L 
Improvement 
of skin and 
lung inv., 
healing of 
digital ulcers 
and 
capillaroscop
ic alterations nd na 
14 
Jordan S et 
al.,2014 46° 
RTX 1g/2wks 
for 2 times                 
(in the 
majority of 
cases) 1 7 S, L 
Improvement 
of skin inv., 
and 
prevention of 
progression 
of lung 
fibrosis (n=9 
pts) nd 
Absence of 
serious 
adverse 
events; 
cardiac/renal 
inv. and 
arrhythmia 
was reported 
in 1 pt each. 
Fatigue was 
noted in 14/56 
(25%), 
infections in 
11/53 (21%), 
nausea in 
2/48 (4%) and 
rigour in 3/48 
(6%). Serum 
sickness/hype
rsensitivity 
reaction was 
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observed in 
2/54 (4%) pts. 
15 Bosello S, 2015 20 
RTX 1g/2wks 
for 2 times 1*** 
48,5±2
0,4 S, L, A 
Improvement 
of both skin 
and lung 
inv., and 
arthritis in 
5/5; 
prevention of 
lung fibrosis 
progression  nd 
4 events (3 
probably 
unrelated to 
RTX); 2 pts 
died: one pt 
with long dis 
dur due to 
heart failure 
30 mths after  
last RTX 
infusion and 1 
due to sudden 
death 39 mths 
after RTX. 1 
pt developed 
herpes zoster 
infection 1 
month after 
third course of 
RTX and 1 
presented an 
occult breast 
cancer after 6 
mths from 
RTX.  
16 present series 10 
RTX 
375mg/m2/wk 
for 4 weeks   1-5 37±21 
S, L, A, 
DU 
Improved 
mRSS in pts 
with diffuse 
cutaneous 
SSc, 
calcinosis, 
and arthritis nd 
infusion-
related 
reactions in 
2/10 pts 
(hypotension,  
mild urticaria , 
and serum 
sickness-like 
reaction).   1 
pt developed 
infection of 
urinary tract 
needing 
hospitalization
. 
^extension of the study no. 6; °from the first RTX 
cycle 
*Involvement of: skin (S), lung(L), calcinosis (C); 
arthritis (A); digital ulcers (DU) 
  ** RTX 500 mg time 0-14 every 3 months for 1 
year 
***8 pts were treated with two or more courses 
of RTX during the follow-up 
°modified Rodnan skin score (mRSS) was available fo r 
statistical analysis in 46/63 enrolled patients  
FU: follow up, RTX: Rituximab, wk: week, wks: 
weeks, 
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FVC: forced vital capacity, DLCO: diffusing capacity of the lung for carbon monoxide  
HRCT: High-resolution computed tomografhy 
n: not done; na: not 
available 
 
